Fabrication of Cyclodextrins Particles and Super Porous Cryogels for Solubilization and Extended Delivery of Multiple Hydrophobic/lipophilic Drugs and Toxic Chemicals

Tech ID: 23T016

­Advantages:

  • Enhanced Therapeutic Effectiveness: It improves the efficacy of drug treatments by enhancing solubility and bioavailability.
  • Customizable Drug Delivery: Offers tailored drug release profiles and the ability to deliver multiple drugs simultaneously.
  • Cross-Industry Applicability: Finds applications in pharmaceuticals, environmental cleanup, and biomedical research due to its versatile properties.

Summary:

In the fields of pharmaceuticals and environmental science, persistent challenges revolve around the effective delivery and separation of hydrophobic and lipophilic compounds due to issues such as poor solubility and limited bioavailability. To address these scientific hurdles, this technology leverages the remarkable properties of cyclodextrins (CDs), cyclic oligosaccharides derived through enzymatic degradation of starch. CDs, encompassing alpha (α-), beta (β-), and gamma (γ-) cyclodextrins, exhibit a distinctive toroidal structure characterized by a hydrophobic core and hydrophilic outer regions. Their exceptional feature lies in the formation of inclusion complexes with hydrophobic compounds, significantly enhancing solubility and bioavailability, a vital aspect in pharmaceutical research.

 

Scientific endeavors have yielded substantial results, prominently in the development of polymeric particles and super porous cryogels utilizing α-, β-, and γ-cyclodextrins. These materials represent a significant scientific achievement by efficiently encapsulating hydrophobic drugs, allowing precise control of release kinetics, and augmenting bioavailability. Rigorous scientific investigations, including comprehensive testing and analysis, underscore the credibility of this approach. Expanding beyond the pharmaceutical domain, this technology finds practical application in environmental remediation and biomedical research. With demonstrated biocompatibility and blood compatibility suitable for in vivo applications, this research is grounded in sound scientific principles. This technology represents a substantial advancement in tackling solubility challenges and compound separation complexities, promising transformative contributions to healthcare and environmental sciences.

(a) The reaction schema of particle preparation fromo-, B-, or Y-Cyclodextrin and (b) The SEM images of poly(a-Cyclodextrin) (p(a-CD), poly(-Cyclodextrin) (p(-CD)), or poly-Cyclodextrin) (ply-CD))

Desired Partnerships:

  • License
  • Sponsored Research
  • Co-Development

Technology Transfer
TTOinfo@usf.edu
(813) 974-0994

Patents